Clinical Trial Update: Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial exploring neoadjuvant afatinib in combination with chemotherapy for stage IIa-IIIb non-small cell lung cancer with EGFR activating mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University | Conditions: Non Small Cell Lung Cancer, Surgery | Phase 2 | Status: UNKNOWN